多瑞医药
(301075)
| 流通市值：16.86亿 | | | 总市值：16.86亿 |
| 流通股本：8000.00万 | | | 总股本：8000.00万 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 255,400,920.06 | 271,692,853.48 | 326,221,492.71 | 405,270,705.96 |
| 应收票据及应收账款 | 95,612,720.16 | 104,959,770.82 | 83,179,837.79 | 82,235,812.18 |
| 其中：应收票据 | 51,992 | 328,423.7 | 330,268 | 2,499,470.93 |
| 应收账款 | 95,560,728.16 | 104,631,347.12 | 82,849,569.79 | 79,736,341.25 |
| 应收款项融资 | 1,274,540.6 | 39,138 | 39,138 | 3,270,875.7 |
| 预付款项 | 36,751,148.34 | 28,007,276.65 | 30,673,639.99 | 26,686,990.33 |
| 其他应收款合计 | 9,698,907.64 | 9,898,253.51 | 13,652,811.94 | 11,197,973.18 |
| 存货 | 60,124,369.99 | 43,822,959.35 | 31,374,246.99 | 33,128,080.17 |
| 其他流动资产 | 14,864,220.59 | 11,665,245.92 | 10,166,049.03 | 9,592,593.37 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 615,258,719.27 | 611,337,482.67 | 682,373,216.45 | 648,948,030.89 |
| 非流动资产: | | | | |
| 长期股权投资 | 100,057,081.08 | 98,415,655.71 | 87,055,807.98 | 85,752,304.16 |
| 其他权益工具投资 | 70,795,388.23 | 67,795,388.23 | 78,795,388.23 | 69,605,388.23 |
| 固定资产 | 199,530,897.21 | 192,560,562 | 192,089,320.64 | 199,840,159.36 |
| 在建工程 | 9,931,286.09 | 19,046,741.94 | 16,740,365.5 | 9,081,577.9 |
| 使用权资产 | 2,755,115.02 | 2,755,115.02 | 733,204.51 | 879,845.42 |
| 无形资产 | 33,375,856.65 | 33,657,575.07 | 33,930,001.41 | 34,191,536.66 |
| 商誉 | 3,892,258.96 | 3,894,710.5 | 3,881,342.55 | 3,685,495.93 |
| 长期待摊费用 | 2,715,737.83 | 2,777,195.26 | 3,352,315.83 | 2,700,160.12 |
| 递延所得税资产 | 1,186,743.32 | 1,208,258.73 | 1,299,507.98 | 1,253,774.13 |
| 其他非流动资产 | 30,505,505.25 | 17,076,562 | 16,176,562 | 16,327,323.75 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 454,745,869.64 | 439,187,764.46 | 434,053,816.63 | 423,317,565.66 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,070,004,588.91 | 1,050,525,247.13 | 1,116,427,033.08 | 1,072,265,596.55 |
| 流动负债: | | | | |
| 短期借款 | 25,024,937.5 | 25,024,937.5 | 74,942,925.06 | 50,129,622.69 |
| 应付票据及应付账款 | 42,300,927.04 | 23,671,214.53 | 18,057,407.45 | 26,765,308.37 |
| 其中：应付票据 | - | - | - | 2,399,998 |
| 应付账款 | 42,300,927.04 | 23,671,214.53 | 18,057,407.45 | 24,365,310.37 |
| 合同负债 | 2,398,644.02 | 2,059,769.52 | 3,248,667.35 | 5,082,944.81 |
| 应付职工薪酬 | 3,924,295.43 | 3,595,450.1 | 3,032,771.49 | 5,687,463.95 |
| 应交税费 | 672,002.37 | 3,520,167 | 2,866,037.94 | 5,332,261.7 |
| 其他应付款合计 | 12,394,339.72 | 11,766,007.43 | 11,533,361.1 | 21,876,159.62 |
| 一年内到期的非流动负债 | 46,604,185.5 | 3,598,018.84 | 11,603,336.89 | 11,603,336.89 |
| 其他流动负债 | 311,823.73 | 267,770.04 | 422,326.76 | 2,702,587.43 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 133,631,155.31 | 73,503,334.96 | 125,706,834.04 | 129,179,685.46 |
| 非流动负债: | | | | |
| 长期借款 | 165,065,777.78 | 188,118,844.44 | 188,216,919.88 | 118,080,017.1 |
| 租赁负债 | 2,183,024 | 2,183,024 | 313,761.41 | 306,000 |
| 递延收益 | 2,089,053.27 | 2,099,803.26 | 2,110,553.25 | 2,121,303.24 |
| 递延所得税负债 | 888,160.91 | 892,618.26 | 897,075.61 | 901,532.96 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 170,226,015.96 | 193,294,289.96 | 191,538,310.15 | 121,408,853.3 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 303,857,171.27 | 266,797,624.92 | 317,245,144.19 | 250,588,538.76 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 80,000,000 | 80,000,000 | 80,000,000 | 80,000,000 |
| 资本公积 | 509,053,958.47 | 509,077,457.35 | 509,115,069.23 | 509,217,874.62 |
| 减:库存股 | 20,991,708.87 | 20,991,708.87 | 19,999,010.49 | - |
| 其他综合收益 | 676,095.18 | 676,095.18 | 795,406.09 | 676,095.18 |
| 盈余公积 | 20,260,274.89 | 20,260,274.89 | 20,260,274.89 | 20,260,274.89 |
| 未分配利润 | 134,971,536.73 | 148,773,863.53 | 159,373,371.17 | 161,910,647.31 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 723,970,156.4 | 737,795,982.08 | 749,545,110.89 | 772,064,892 |
| 少数股东权益 | 42,177,261.24 | 45,931,640.13 | 49,636,778 | 49,612,165.79 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 766,147,417.64 | 783,727,622.21 | 799,181,888.89 | 821,677,057.79 |
| 负债和股东权益合计 | 1,070,004,588.91 | 1,050,525,247.13 | 1,116,427,033.08 | 1,072,265,596.55 |
| 公告日期 | 2024-10-25 | 2024-08-27 | 2024-04-25 | 2024-04-18 |
| 审计意见(境内) | | | | 标准无保留意见 |